Hartford多因子美股ETF ROUS 深 沪
等待开盘 02-06 09:30:00 美东时间
59.80
-0.280
-0.47%
华盛通- 最 高60.107
- 今 开59.70
- 成交量 2.67万股
- 最 低 59.6021
- 昨 收 60.08
- 总市值 5.20亿
- 52周最高 60.86
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 43.6654
- 委 比 0.00%
- 总股本 870.00万
- 历史最高 60.86
- 量 比 0.60
- 振 幅 0.84%
- 历史最低 13.8663
- 每 手 1
- 风险率 3.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-HP Inc Announces Leadership Transition
BRIEF-HP Inc Announces Leadership Transition Feb 3 (Reuters) - HP Inc HPQ.N : HP INC. ANNOUNCES LEADERSHIP TRANSITION HP INC - APPOINTS BRUCE BROUSSARD AS INTERIM CEO HP INC - REAFFIRMS FIRST QUARTER AND FISCAL 2026 OUTLOOK HP INC - ENRIQUE LORES STEPS DOWN AS PRESIDENT AND CEO Source text: ID:nGNX6
02-03 21:28
UPDATE 2-Millions of Americans, digging out after monster storm, face days of bitter cold
UPDATE 2-Millions of Americans, digging out after monster storm, face days of bitter cold Power outages across southern states, Tennessee worst hit Bitter cold expected to persist for days 'Feel free to throw snowball at me' quips NY mayor as he shuts schools Adds updated weather forecast, details o
01-26 18:13
BRIEF-JPMorgan Reports Q4 EPS $4.81
Jan 15 (Reuters) - JPMorgan Chase & Co JPM.N: JPMORGAN Q4 EPS $4.81 JPMORGAN Q4 REVENUE $42,768 MILLION JPMORGAN Q3 CREDIT LOSS PROVISION $2,631 MILLION JPMORGAN - ONGOING AND FUTURE SPENDING REQUIREM...
2025-01-15 19:56
BRIEF-Nippon Steel: Cleveland-Cliffs CEO Gonclaves 'Continues To Persist With Biased Stereotypes'
Jan 14 (Reuters) - Nippon Steel Corp 5401.T: WE REMAIN THE ONLY PARTNER FOR U. S. STEEL THAT CAN KEEP THE COMPANY INTACT AND THE BLAST FURNACES RUNNING, PROTECT JOBS OUR COMMITMENTS HAVE BEEN DEVELOPE...
2025-01-14 11:02
BRIEF-Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA
Jan 13 (Reuters) - Verastem Inc VSTM.O: VERASTEM ONCOLOGY ANNOUNCES DEBT REFINANCING WITH OBERLAND CAPITAL AND STRATEGIC COMMERCIALIZATION PARTNERSHIP WITH IQVIA TO SUPPORT POTENTIAL LAUNCH IN RECURRE...
2025-01-13 21:50
BRIEF-Palvella Therapeutics Doses First Patients In Phase 2 Toiva Clinical Trial Of Qtorin
Jan 8 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 TOIVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR...
2025-01-08 22:00
